HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $75

Benzinga Newsdesk www.benzinga.com Positive 79.1%

Neg 0% Neu 0% Pos 79.1%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $60 to $75.